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sideration in the literature [13]. As a result, the findings 
obtained in this investigation may be applicable to the study 
of PMA in other cell systems. According to Augustins- 
son [S], each esterase type exists in multiple forms and each 
animal species has its own typical spectrum of esterases in 
plasma and tissues [14]. In the presence of marked vari- 
ations in location, form and activity, one might expect sig- 
nificant differences in the effects of drugs which stimulate or 
inhibit these enzymes in different species. If the pharmacolo- 
gical action of a drug is dependent on ester groups, then the 
presence of esterases in all affected cells and tissues would 
have to be considered in evaluating the influence of the 
agent. PMA has been used extensively as a co-carcinogen in 
animal studies [13]. It would be of interest to determine if 
endogenous esterases or the concomitant use of esterase 
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Drug and fatty acid hydroxylation by solubilized human liver 
microsomal cytochrome P_45t&Phospholipid requirement* 
(Received 15 March 1974; accepted 7 June 1974) 
The enzyme system in rabbit liver microsomes which cata- 
lyzes the hydroxylation of a variety of fatty acids, hydrocar- 
bons, drugs and other foreign compounds was solubilized 
by Lu and Coon [l, 21, and resolved into three components: 
cytochrome P-450, NADPH-cytochrome P-450 reductase, 
and a heat-stable substance called Factor B [3]. The heat- 
stable component was identified as phosphatidylcholine and 
was shown to be essential for the reductase-catalyzed 
transfer of electrons from NADPH to cytochrome P-450 
[4]. Synthetically prepared compounds such as lauroylgly- 
ceryl-3-phosphorylcholine (lauroyl-GPC) were found to be 
active when substituted for the microsomal phosphatidyl- 
choline fraction. Subsequently, the corresponding enzyme 
systems in rat [5,6] and mouse [7] liver microsomes as 
well as in a yeast, Candida tropicalis [8,9]. were reconsti- 
tuted by similar procedures. The cytochrome P-448-con- 
taining enzyme system, which oxidizes polycyclic aromatic 
carcinogens, was also reconstituted and was found to 
* This work was supported by the National Science 
Foundation (Grant GB-30419X) and the United States Pub- 
lic Health Service (Grant AM-10339). A preliminary report 
of this investigation has been presented (Fifth International 
Congress on Pharmacology, San Francisco, Calif., 1972). 
require the reductase and phosphatidylcholine for activity, 
as shown with 3-methylcholanthrene-treated rats [lo] and 
p-naphthoflavone-treated mice of both inducible and nonin- 
ducible strains [7]. 
The present paper describes the solubilization of human 
liver microsomal cytochrome P-450 and its reconstitution 
into a functional hydroxylating system by the addition of 
the reductase and phosphatidylcholine. The presence of 
cytochrome P-450 in human liver microsomes was first 
reported by Alvares et al. [ll], and the hydroxylation of 
various substrates has been shown to occur in the microso- 
ma1 fraction obtained from human liver biopsy samples 
[12, 131, fetal liver [14], and postmortem liver from patients 
with abnormal medical histories [15] or apparently normal 
individuals who met sudden deaths [16]. 
A liver sample from a 21-year-old male who had met an 
accidental death about 4 hr previously was cut into pieces, 
washed with 025 M sucrose and frozen. All procedures were 
carried out at 4” unless stated otherwise. The microsomal 
fraction was isolated according to Nelson et al. [16], except 
that 05 mM dithiothreitol was added to all solutions, and 
was stored at - 20” under nitrogen. The yield of microsomal 
protein was 13 mg/g of liver, wet wt. Cytochrome P-450 and 
P-420 were present in the amounts of 0.25 and 0.42 nmole/ 
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Fig, 1. The complete reaction mixture contained the human 
liver cytochrome P-450 fraction (0.62 nmole; 1.3 mg pro- 
tein), rat liver NADPH-cytochrome P-450 reductase frac- 
tion [3] (0.03 mg protein), lauroyl-GPC (0.05 mg). d-benz- 
phetamine (1.0 pmole), potassium phosphate buffer, pH 7.7 
(100 fitmoles) and NADPH (0.1 Itmole) as the last addition 
in a final volume of 1.0 ml. Curve A, complete system; curve 
B, benzphetamine omitted; curve C, phosphatidylcholine 
omitted; and curve D, cytochrome P-450 fraction omitted. 
The temperature was 30”. 
mg of protein respectively. Microsomes were thawed, solu- 
bilized with cholate, and fractionated with ammonium sul- 
fate by a modifi~tion of procedures used previously with 
rat liver microsomes 1173. The preparation was centrifuged 
at 100,000 9 for 1 hr to remove turbidity, and the extract was 
treated with solid ammonium sulfate. The precipitate 
formed at 35% salt saturation was removed by centrifuga- 
tion and discarded, and the supernatant fraction was 
brought to 45 per cent saturation with ammonium sulfate. 
The floating precipitate, which separated on centrifugation, 
was dissolved in 30 ml of 0.1 M Tris-chloride buffer, pH 7.4, 
containing 20% glycerol and 05 mM dithiothreitol, and the 
solution was then brought to 45 per cent saturation with 
ammonium sulfate. The resulting floating precipitate was 
taken up in 5 ml of the same buffer mixture and centrifuged 
for 1 hr at l~,~O 9. The supernatant fraction was used as 
the source of cytochrome P-450 in the experiments to be de- 
scribed. This procedure was devised to obtain purification 
rather than high yield. 
The ability of the solubilized cytochrome P-450 to cata- 
lyze benzphetamine ~-demethylation was determined by a 
s~ctrophotome~ic assay in which substrate-dependent 
NADPH disappearance was determined at 340 nm [S, 61. 
The results presented in Fig. 1 indicate that drug hydroxy- 
iation was linear with time for at least 8 mm, and that the 
reaction was completely dependent on the presence of the 
cytochrome P-450 fraction. Upon the omission of either 
benzphetamine or phospholipid, the rate of NADPH oxi- 
dation was reduced. The rate in the absence of benzpheta- 
mine apparently represents electron flow from NADPH to 
oxygen via the reductase and cytochrome P-450 due to the 
autoxidizability of the latter, as has previously been 
observed with the rat and rabbit liver reconstituted micro- 
somal enzyme systems [6]. In the absence of lauroyl-GPC, 
the rate was reduced to less than that with substrate omit- 
ted; it is evident, therefore, that cytochrome P-450 from 
human liver, like that from the liver of several animal spe- 
cies studied, requires phospholipid for catalytic activity. The 
rate of benzphe~mine demethylation, estimated in such ex- 
periments as 15 nmoles/min/nmole of cytochrome P-450, 
was also determined by direct measurement of formalde- 
hyde formation by the method of Nash [ZO], as modified by 
Cochin and Axelrod [21] with similar results. In qther ex- 
periments, aminopyrine and hexane appeared to be hydrox- 
ylated by the reconstituted enzyme system, as judged by the 
spectrophotometric assay, but the results were not con- 
firmed by direct determination of products formed. 
Evidence was obtained that the reconstituted enzyme sys- 
tem also hydroxylates laurate, as shown in Table 2. Lauroyl- 
GPC appeared to be about as effective as microsomal lipid 
fraction (Fraction B) in supporting this reaction, whereas 
upon omission of phospholipid the rate of hydroxylation 
dropped to about one-fifth the value. Fatty acid hydroxyl- 
ation in human liver microsomal suspensions has also been 
described by Yaffe et al. [i4]. 
Cytochrome P-450 and cytochrome P-420 were estimated The results presented indicate that human liver cyto- 
according to Omura and Sato [is], except that both chrome P-450 can be solubilized from microsomal mem- 
cuvettes were bubbled with CO and dithionite was added to branes by procedures previously applied successfully to liver 
one, thereby preventing interference by any hemoglobin microsomes of other species and may be partially purified 
con~minating the samples. Protein concentrations were 
determined according to Lowry et al. [19]. Lauroyl-GPC, 
a 5: 1 mixture of the di- and mono-lauroyl compounds, was 
a gift from Dr. W. E. M. Lands. 
The cytochrome P-450 content of the human liver micro- 
somes, as shown in Table 1, was in the range reported by 
others for comparable liver samples [16]. The extraction 
procedure caused a slight decrease in the cytochrome P-450 
content, but fractionation with ammonium sulfate yielded a 
preparation in which the cytochrome P-450 was purified 
about 2-fold with respect to the microsomes and the cyto- 
chrome P-420 was largely removed. 







suspension 0.25 0.42 
Cholate extract 0.17 (0.14-0.21) 0.4 t (0.34-0.52) 
Ammonium sulfate 
precipitate 
(045% saturation) 0.48 (0.38-054) 0.07 (&o, 12) 
* The values given are an average, and the numbers in parentheses indicate the range obtained with the cholate extract 
(four experiments) and the ammonium sulfate fraction (five experiments). 
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(Fraction B) (0.05 mg) 
Lauroyl-GPC (0.05 mg) 
None 
2 0.32 (025-0.39) 
5 0.27 (021-0.32) 
I 0.06 (0.01-0.12) 
* The reaction mixture was similar to that in Fig. 1, except that the substrate was I-14C-laurate (0.25 mM, final con- 
centration) and the incubation time was 15 min. The radioactive hydroxylaurate formed was isolated by silicic acid chro- 
matography [22]. The values given are an average of several experiments, and the numbers in parentheses indicate the 
range. 
and freed of contaminating cytochrome P-420 by fractiona- 
tion with ammonium sulfite. The resulting enzyme prepara- 
tion catalyzes the hydroxylation of benzphetamine and lau- 
rate, but exhibits maximal activity in such reactions only 
when supplemented with phosphatidylcholine. Stopped flow 
measurements have shown that, in the reconstituted system 
from rat liver microsomes, electron transfer from NADPH 
to cytochrome P-450 occurs at a rate sufficiently rapid to 
support substrate hydroxylation only when phosphatidyl- 
choline is present [4]. In addition, evidence has been 
obtained that the phospholipid may form a dissociable com- 
plex with cytochrome P-450 and the NADPH-cytochrome 
P-450 reductase, but that large aggregates or membrane-like 
structures are not produced, as judged by such techniques 
as sedimentation, gel exclusion chromatography and elec- 
tron microscopy [17]. On the other hand, the manner in 
which the phospholipid acts is not yet understood at a 
detailed mechanistic level. 
It should be noted that human liver microsomes are lqwer 
in cytochrome P-450 content than are microsomes from 
commonly used laboratory animals. Furthermore, the solu- 
bilized human liver microsomal cytochrome P-450 appears 
to be more labile than that from rat or rabbit and is more 
difficult to purify because of the presence of large amounts 
of lipid. Accordingly, despite the obvious importance of elu- 
cidating the manner in which the human liver enzyme sys 
tern metabilizes drugs and a variety of other foreign com- 
pounds, it appears that more rapid progress may be made 
by first isolating and characterizing the individual com- 
ponents from other species in which liver is a richer source 
of this enzyme system [23]. The present study indicates that, 
despite some particular difficulties in working with the sys- 
tem from human liver, the cytochrome P-450 may be solubi- 
lized by a detergent in the presence of glycerol as a stabiliz- 
ing agent and that the presence of phospholipid is necessary 
for activity. Whether an electron acceptor other than the 
iron atom is present in the human liver cytochrome P-450 
preparation, as was recently shown for the partially purified 
rabbit liver cytochrome P-450 [24], remains to be estab- 
lished. 
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